From staff reports

 is making it easier for pharmacists and healthcare professionals to look up drug information by launching an online scientific resource tool.

, is available to view on computers, tablets, and smartphones.

"JanssenMD was created to provide healthcare professionals with theinformation they need, when, where, and how they need it," said Dr. NormRosenthal, Chief Scientific Officer, Janssen Scientific Affairs, LLC.

The online resource provides prescribing information, clinical trial data, and safety information about Janssen medications, according to a press release.

"This unique digital platform enables us to respond to healthcare professionals'questions with information that is current, accurate, and instantlyaccessible from any device they are using," Rosenthal said.

Articles

Janssen Pharmaceuticals, Inc. is making it easier for pharmacists and healthcare professionals to look up drug information by launching an online scientific resource tool.

New online tool available for Janssen products

, Abbott) for inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis (UC) when certain other medicines have not worked well enough. Combined with its approval to treat moderate-to-severe Crohn's disease, adalimumab is now approved for the treatment of the 2 primary diseases that comprise inflammatory bowel disease.

Adalimumab works by inhibiting tumor necrosis factor-alpha (TNF-α). The UC approval represents the seventh indication for this treatment in the United States and makes adalimumab the first and only self-administered biologic treatment approved for use in this disease. It is not known if adalimumab is effective in people with moderate to severe UC who have lost response to or could not tolerate anti-TNF medicines. Adalimumab can be self-administered after proper injection training is received and with proper physician monitoring.

"There is significant unmet medical need in this patient population, which has not seen a new treatment approved in more than seven years," William J. Sandborn, MD, division chief, gastroenterology, University of California, San Diego, said in an Abbott press release. "This FDA approval is good news for patients and health care professionals who are seeking another option to manage the disease."

UC is a chronic disease that is marked by inflammation and ulceration in the lining of the colon or large intestine. It is estimated that approximately 700,000 people in the United States have UC. On average, people are diagnosed with UC in their mid-30s, though the disease can occur at any age. Symptoms include abdominal cramping, rectal bleeding, diarrhea, and urgency and frequency to have a bowel movement. The symptoms of UC tend to come and go, with periods of remission between flare-ups. Treatment may include medication and surgery.

It is also important that UC patients properly manage their nutrition because fluids, nutrients and electrolytes can be lost due to rectal bleeding and diarrhea. Additionally, 25% of UC patients will require surgery during the course of the disease.

FDA previously approved Humira to treat rheumatoid arthritis (2002), psoriatic arthritis (2005), ankylosing spondylitis (2006), Crohn’s disease (2007), plaque psoriasis (2008), and juvenile idiopathic arthritis (2008).

Abbott's submission for Humira was supported by results from 2 phase 3 studies, ULTRA 1, an 8-week study, and ULTRA 2, a 52-week study, both of which enrolled adult patients who had moderately to severely active UC despite concurrent or prior treatment with immunosuppressants (ie, corticosteroids, azathioprine, or 6-mercaptopurine).

The primary end point of both studies was the proportion of patients achieving clinical remission at specified time points (week 8 in ULTRA 1 and weeks 8 and 52 in ULTRA 2). Remission was defined as a Mayo score of ≤ 2 and no individual subscore > 1. The Mayo score is calculated based on subscores of stool frequency, rectal bleeding, physician's global assessment, and endoscopy. In the FDA-approved dose, both studies achieved their primary end points. The safety results from both studies were consistent with the known safety profile of adalimumab and no new safety signals were identified.

Adalimumab is a TNF blocker medicine that affects the immune system and can lower the ability to fight infections. Serious infections have happened in people taking adalimumab. These serious infections include tuberculosis (TB) and infections caused by viruses, fungi, or bacteria that have spread throughout the body. Some people have died from these infections. People should be tested for TB before adalimumab use and monitored for signs and symptoms of TB during therapy. People at risk of TB may be treated with medicine for TB. Treatment with adalimumab should not be started in a person with an active infection, unless approved by a doctor. Adalimumab should be stopped if a person develops a serious infection. People should tell their doctor if they live in or have been to a region where certain fungal infections are common, have had TB, hepatitis B, are prone to infections, or have symptoms such as fever, fatigue, cough, or sores.

For people taking TNF blockers, including adalimumab, the chance of getting lymphoma or other cancers may increase. Some people have developed a rare type of cancer called hepatosplenic T-cell lymphoma. This type of cancer often results in death. If using TNF blockers including adalimumab, the chance of getting 2 types of skin cancer (basal cell and squamous cell) may increase. These types are generally not life threatening if treated.

Common side effects of adalimumab include injection-site reactions (redness, rash, swelling, itching, or bruising), upper respiratory infections (including sinus infections), headaches, rash, and nausea.

FDA has approved adalimumab (Humira, Abbott) for inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis (UC) when certain other medicines have not worked well enough. Combined with its approval to treat moderate-to-severe Crohn's disease, adalimumab is now approved for the treatment of the 2 primary diseases that comprise inflammatory bowel disease.

FDA approves Humira to treat ulcerative colitis

) tablets for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with currently available therapies (including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy). 

Regorafenib is an oral multi-kinase inhibitor that inhibits various kinases within the mechanisms involved in tumor growth and progression-angiogenesis, oncogenesis, and the tumor microenvironment. 

Regorafenib’s approval is based on results from the pivotal phase 3 (CORRECT [or (Colorectal cancer treated with regorafenib or placebo after failure of standard therapy]) study that demonstrated a statistically significant improvement in overall survival (OS) and progression-free survival (PFS) compared to placebo in patients with mCRC whose disease had progressed after approved standard therapies. 

 “The US approval of Stivarga is an important milestone for Bayer as it marks the first approval of this innovative cancer treatment to fulfill a significant unmet medical need in the treatment of metastatic colorectal cancer,” Jörg Reinhardt, CEO, Bayer HealthCare, said in a company press release. 

In the CORRECT trial, regorafenib plus best supportive care (BSC) significantly improved OS (HR=0.77, 2-sided 

The most frequently observed adverse drug reactions (≥30%) in patients receiving regorafenib were asthenia/fatigue, decreased appetite and food intake, hand-foot-skin reaction/palmar-plantar erythrodysesthesia, diarrhea, mucositis, weight loss, infection, hypertension, and dysphonia. The most serious adverse drug reactions in patients receiving regorafenib were hepatotoxicity, hemorrhage, and gastrointestinal perforation. Primary efficacy and safety data for this trial were first reported at the Annual Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI) in January 2012 and additional data were presented at the ASCO Annual Meeting in June 2012. 

Stivarga was developed and reviewed under the fast track program and received priority review designation from FDA. 

CRC is the fourth most common cancer worldwide, with more than 1 million cases occurring every year. The mortality rate from CRC is approximately half of its global incidence. The 5-year survival estimate for CRC on average is 55%, but is highly variable dependent on the stage of the disease (from 74% for patients with stage I disease to only 6% for stage IV patients).   In mCRC, KRAS status is an important biomarker and can be a predictor of treatment response. Approximately 40% of colorectal cancers are characterized by mutations in the KRAS gene. Some of the CRC therapies currently available have demonstrated efficacy only in patients without KRAS mutations.  

FDA approved regorafenib (Stivarga, Bayer HealthCare) tablets for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with currently available therapies (including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and if KRAS wild type, an anti-EGFR therapy).

FDA approves regorafenib tablets for treatment of metastatic colorectal cancer

is supporting antibacterial drug development by launching a new internal task force.

"The creation of this new task force comes at a critical time," said Edward Cox, MD, MPH, director of the Office of Antimicrobial Products in FDA's Center for Drug Evaluation and Research (CDER) and co-chair of the task force. "Establishing new ways of developing safe and effective new antibacterial drugs is an enormous challenge and not an effort that can be accomplished alone."

The task force will identify priority areas and potential solutions to the challenges of antibacterial drug development, according to the 

. There are 19 CDER  scientists and clinicians on the task force. 

“More than 70% of the bacteria that cause hospital-associated infections (HAIs) are resistant to at least one type of antibacterial drug most commonly used to treat these infections," according to the statement. "In the United States, nearly 2 million Americans developed HAIs in 2002, resulting in about 99,000 deaths."

The task force will help develop and revise guidance related to antibacterial drug development, as required by the Generating Antibiotic Incentives Now (GAIN) Title of the FDA Safety and Innovation Act (FDASIA), which was signed into law July 9.

"By establishing this task force, FDA can help make real progress and change the paradigm," said Rachel Sherman, MD, associate director for Medical Policy in CDER, director of CDER's Office of Medical Policy, and co-chair of the task force in the release. "Our hope is that this effort will result in important new breakthroughs in the field of antibacterial drug development and help in the fight against antibiotic resistance."

------------------------------------------------------------

FDA is supporting antibacterial drug development by launching a new internal task force, according to a press release today.

From staff reports

Articles

New online tool available for Janssen products

FDA approves Humira to treat ulcerative colitis

FDA approves regorafenib tablets for treatment of metastatic colorectal cancer

FDA task force to work on antibacterial drug development